Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Raymond James Financial

Key Points

• Regeneron Pharmaceuticals has been upgraded by Raymond James Financial to a "moderate buy" rating, reflecting improved analyst sentiment towards the stock.
• The stock currently has an average target price of $817.67 and various ratings from analysts, with three assigning a Strong Buy, seventeen giving a Buy rating, and one rating it as a Sell.
• In its latest earnings report, Regeneron reported an EPS of $12.89, significantly surpassing expectations and indicating a revenue growth of 3.6% year-over-year.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) was upgraded by Raymond James Financial to a "moderate buy" rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other analysts have also recently commented on REGN. Jefferies Financial Group lifted their target price on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research note on Wednesday, August 27th. Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Canaccord Genuity Group reiterated a "buy" rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Finally, JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Stock Down 2.4%

REGN stock opened at $563.80 on Tuesday. The stock has a market capitalization of $59.76 billion, a P/E ratio of 14.21, a PEG ratio of 1.93 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $1,182.31. The company has a 50 day moving average price of $560.61 and a two-hundred day moving average price of $586.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the previous year, the company earned $11.56 EPS. As a group, sell-side analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 31 shares during the period. Activest Wealth Management raised its stake in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 21 shares during the period. Costello Asset Management INC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $27,000. Finally, Saudi Central Bank purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $27,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.